All Stories

  1. Connexin Expression in Pituitary Adenomas and the Effects of Overexpression of Connexin 43 in Pituitary Tumor Cell Lines
  2. Post-COVID-19 Condition: Where Are We Now?
  3. The ringworm campaign in Portugal, 1940–1970
  4. Performance of the Bethesda System for Reporting Thyroid Cytology in Multi-Institutional Large Cohort of Pediatric Thyroid Nodules: A Detailed Analysis
  5. The Multifaceted Profile of Thyroid Disease in the Background of DICER1 Germline and Somatic Mutations: Then, Now and Future Perspectives
  6. <b><i>TERT</i></b> Promoter Mutational Status in the Management of Cutaneous Melanoma: Comparison with Sentinel Lymph Node Biopsy
  7. Ubiquitin-Specific Proteases: Players in Cancer Cellular Processes
  8. LRP1B: A Giant Lost in Cancer Translation
  9. Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study
  10. Genetic Determinants for Prediction of Outcome of Patients with Papillary Thyroid Carcinoma
  11. Integrated Metabolomics and Transcriptomics Analysis of Monolayer and Neurospheres from Established Glioblastoma Cell Lines
  12. Molecular Pathology of Non-familial Follicular Epithelial–Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification
  13. Correlation of molecular data with histopathological and clinical features in a series of 66 patients with medullary thyroid carcinoma
  14. LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer
  15. Mohs Micrographic Surgery for Head and Neck Nonmelanoma Skin Cancer: An Approach for Ent Surgeons
  16. S616-p-DRP1 associates with locally invasive behavior of follicular cell-derived thyroid carcinoma
  17. Clinicopathological Features as Prognostic Predictors of Poor Outcome in Papillary Thyroid Carcinoma
  18. Molecular Aspects of Thyroid Calcification
  19. Metabolic modulation combined with mTOR pathway inhibition may overcame cutaneous melanoma resistance to MAPK inhibitors treatment
  20. Clinical Validation of a Urine Test (Uromonitor-V2®) for the Surveillance of Non-Muscle-Invasive Bladder Cancer Patients
  21. Follicular Lesions with Papillary Nuclear Characteristics: Differences in Chromatin Detected by Computerized Image Analysis
  22. Analyzing the Role of DICER1 Germline Variations in Papillary Thyroid Carcinoma
  23. Predictive Biomarkers and Patient Outcome in Platinum-Resistant (PLD-Treated) Ovarian Cancer
  24. Comprehensive Assessment of TERT mRNA Expression across a Large Cohort of Benign and Malignant Thyroid Tumours
  25. Prognostic Significance of RAS Mutations and P53 Expression in Cutaneous Squamous Cell Carcinomas
  26. Erratum to “Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism”
  27. A 30-Year Long-Term Experience in Appendix Neuroendocrine Neoplasms—Granting a Positive Outcome
  28. Evaluation of the role of mitochondria in the non-targeted effects of ionizing radiation using cybrid cellular models
  29. Reliable blood cancer cells' telomere length evaluation by qPCR
  30. Head and neck cutaneous basal cell carcinoma: what should the otorhinolaryngology head and neck surgeon care about?
  31. Relevant dose of the environmental contaminant, tributyltin, promotes histomorphological changes in the thyroid gland of male rats
  32. TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients
  33. Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review
  34. Cancer incidence after childhood irradiation for tinea capitis in a Portuguese cohort
  35. Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study
  36. Variants of Papillary Thyroid Carcinoma: An Algorithmic Cytomorphology-Based Approach to Cytology Specimens
  37. Characterization and antitumor activity of the extracellular carbohydrate polymer from the cyanobacterium Synechocystis ΔsigF mutant
  38. Interaction of Genetic Variations inNFE2L2andSELENOSModulates the Risk of Hashimoto's Thyroiditis
  39. Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism
  40. Differential Expression of HMGA1 and HMGA2 in pituitary neuroendocrine tumors
  41. Oncocytic thyroid neoplasms: from histology to molecular biology
  42. “The other side of the coin”: understanding noninvasive follicular tumor with papillary-like nuclear features in unifocal and multifocal settings
  43. TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma
  44. Scalp basal cell carcinoma: A different entity?
  45. Selenium and Selenoproteins in Immune Mediated Thyroid Disorders
  46. The environmental contaminant tributyltin leads to abnormalities in different levels of the hypothalamus-pituitary-thyroid axis in female rats
  47. OPNa Overexpression Is Associated with Matrix Calcification in Thyroid Cancer Cell Lines
  48. Liposomal therapies in oncology: does one size fit all?
  49. Editorial on “The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma”
  50. Follicular thyroid lesions: is there a discriminatory potential in the computerized nuclear analysis?
  51. Unraveling molecular targets of bisphenol A and S in the thyroid gland
  52. TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma
  53. Melanoma treatment in review
  54. Cribriform-morular variant of thyroid carcinoma: a neoplasm with distinctive phenotype associated with the activation of the WNT/β-catenin pathway
  55. mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and SLC5A5 mRNA Expression
  56. Age-Associated Mortality Risk in Papillary Thyroid Cancer: Does BRAF Make a Real Difference?
  57. Telomere Maintenance Mechanisms in Cancer
  58. Tributyltin and Zebrafish: Swimming in Dangerous Water
  59. Genomic and transcriptomic characterization of the mitochondrial-rich oncocytic phenotype on a thyroid carcinoma background
  60. Is Low-Dose Radiation Exposure a Risk Factor for Atherosclerotic Disease?
  61. Multinodular Goiter Progression Toward Malignancy in a Case of DICER1 Syndrome
  62. Dynamin-Related Protein 1 at the Crossroads of Cancer
  63. CRABP1, C1QL1 and LCN2 are biomarkers of differentiated thyroid carcinoma, and predict extrathyroidal extension
  64. NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features
  65. Frontiers in endocrine disruption: Impacts of organotin on the hypothalamus-pituitary-thyroid axis
  66. Etiopathogenesis of oncocytomas
  67. Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer
  68. Calcitonin receptor expression in medullary thyroid carcinoma
  69. Introduction
  70. Other Rare Tumours and Tumour-Like Lesions
  71. Rare Familial Tumours
  72. Rare Follicular Tumours
  73. Rare Papillary Thyroid Carcinomas
  74. Small Cell Tumours
  75. Therapeutic Options
  76. SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanoma
  77. Hobnail Variant of Papillary Thyroid Carcinoma
  78. Telomerase and N-Cadherin in Adrenocortical Tumors
  79. Molecular landscape of metastatic thyroid cancer
  80. The role of ablative treatment in differentiated thyroid cancer management
  81. TERTbiology and function in cancer: beyond immortalisation
  82. pmTOR is a marker of aggressiveness in papillary thyroid carcinomas
  83. TERTpromoter mutations: a genetic signature of benign and malignant thyroid tumours occurring in the context of tinea capitis irradiation
  84. IL6-174 G>C Polymorphism (rs1800795) Association with Late Effects of Low Dose Radiation Exposure in the Portuguese Tinea Capitis Cohort
  85. The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype
  86. Telomerase Activation in Hematological Malignancies
  87. Erratum: Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells
  88. TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes
  89. Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior
  90. Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas
  91. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism
  92. Telomerase promoter mutations in cancer: beyond immortalization?
  93. Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma
  94. TERT Promoter Mutations in Soft Tissue Sarcomas
  95. Thyroid and Parathyroid Glands
  96. Obesity Is Associated With Low NAD+/SIRT Pathway Expression in Adipose Tissue of BMI-Discordant Monozygotic Twins
  97. Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes
  98. Hotspot TERT promoter mutations are rare events in testicular germ cell tumors
  99. RAF-1 promotes survival of thyroid cancer cells harboring RET/PTC1 rearrangement independently of ERK activation
  100. ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome
  101. Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy
  102. Mitochondrial Dynamics Protein Drp1 Is Overexpressed in Oncocytic Thyroid Tumors and Regulates Cancer Cell Migration
  103. RE: TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma
  104. Coexistence of TERT Promoter and BRAF Mutations in Papillary Thyroid Carcinoma: Added Value in Patient Prognosis?
  105. Hashimoto’s Thyroiditis in Adolescents
  106. Poorly differentiated and undifferentiated thyroid carcinomas
  107. OXPHOS dysfunction regulates integrin- 1 modifications and enhances cell motility and migration
  108. mTOR activation in medullary thyroid carcinoma with RAS mutation
  109. Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs)
  110. Differentiated thyroid cancer in patients with resistance to thyroid hormone syndrome. A novel case and a review of the literature
  111. Thyroid and parathyroid tumours in patients submitted to X-ray scalp epilation during the tinea capitis eradication campaign in the North of Portugal (1950–1963)
  112. Polymorphisms in the TNFA and IL6 Genes Represent Risk Factors for Autoimmune Thyroid Disease
  113. TERT Promoter Mutations in Skin Cancer: The Effects of Sun Exposure and X-Irradiation
  114. Telomerase promoter mutations in cancer: an emerging molecular biomarker?
  115. Increased lymphangiogenesis in Riedel thyroiditis (Immunoglobulin G4-related thyroid disease)
  116. TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas
  117. A Polymorphism in the Promoter Region of the Selenoprotein S Gene (SEPS1) Contributes to Hashimoto's Thyroiditis Susceptibility
  118. C-Cell-Derived Calcitonin-Free Neuroendocrine Carcinoma of the Thyroid
  119. Prognostic biomarkers in thyroid cancer
  120. Papillary Thyroid Microcarcinoma
  121. Mitochondrial D310 D-Loop instability and histological subtypes in radiation-induced cutaneous basal cell carcinomas
  122. Primary Squamous Cell Carcinoma of the Thyroid Diagnosed as Anaplastic Carcinoma: Failure in Fine-Needle Aspiration Cytology?
  123. Stimulated Thyroglobulin at Recombinant Human TSH-Aided Ablation Predicts Disease-free Status One Year Later
  124. A founder SDHB mutation in Portuguese paraganglioma patients
  125. Genetic alterations in thyroid tumors from patients irradiated in childhood for tinea capitis treatment
  126. Nrf2 Is Commonly Activated in Papillary Thyroid Carcinoma, and It Controls Antioxidant Transcriptional Responses and Viability of Cancer Cells
  127. Frequency of TERT promoter mutations in human cancers
  128. GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells
  129. Etiopathogenic factors of thyroid cancer
  130. Radiotherapy: radioiodine and external beam irradiation treatment of differentiated thyroid carcinomas
  131. Cribriform-Morular Variant of Papillary Thyroid Carcinoma Displaying Poorly Differentiated Features
  132. CDX2 Expression in Some Variants of Papillary Thyroid Carcinoma
  133. MEN1 intragenic deletions may represent the most prevalent somatic event in sporadic primary hyperparathyroidism
  134. AZD1480 Blocks Growth and Tumorigenesis of RET- Activated Thyroid Cancer Cell Lines
  135. Survey of 548 oncogenic fusion transcripts in thyroid tumors supports the importance of the already established thyroid fusions genes
  136. Molecular alterations and expression of succinate dehydrogenase complex in wild-type KIT/PDGFRA/BRAF gastrointestinal stromal tumors
  137. STAT3 negatively regulates thyroid tumorigenesis
  138. RET/PTCrearrangement is prevalent in follicular Hürthle cell carcinomas
  139. mTOR Pathway Overactivation in BRAF Mutated Papillary Thyroid Carcinoma
  140. Insights into melanoma: targeting the mTOR pathway for therapeutics
  141. TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma
  142. The biology and the genetics of Hurthle cell tumors of the thyroid
  143. Absence of theBRAFand theGRIM-19Mutations in Oncocytic (Hürthle Cell) Solid Cell Nests of the Thyroid
  144. Head and neck basal cell carcinoma prevalence in individuals submitted to childhood X-ray epilation for tinea capitis treatment
  145. The mTOR Signalling Pathway in Human Cancer
  146. Melanocytic Tumour in a Black Sheep never exposed to Ultraviolet Radiation
  147. A Clear Cell Renal Cell Carcinoma Inhibiting the Response to Intravitreal Antivascular Endothelial Growth Factor Therapy in Wet Age-Related Macular Disease
  148. Paraganglioma of seminal vesicle and chromophobe renal cell carcinoma: a case report and literature review
  149. A novel germline SDHB mutation in a gastrointestinal stromal tumor patient without bona fide features of the Carney–Stratakis dyad
  150. Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas
  151. Intratumoural lymph vessel density is related to presence of lymph node metastases and separates encapsulated from infiltrative papillary thyroid carcinoma
  152. Impact of EGFR Genetic Variants on Glioma Risk and Patient Outcome
  153. GRIM-19 function in cancer development
  154. Orthovanadate-induced cell death in RET/PTC1-harboring cancer cells involves the activation of caspases and altered signaling through PI3K/Akt/mTOR
  155. Synergistic growth inhibition of cancer cells harboring the RET/PTC1 oncogene by staurosporine and rotenone involves enhanced cell death
  156. The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases
  157. In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp
  158. Involvement of p53 in cell death following cell cycle arrest and mitotic catastrophe induced by rotenone
  159. Head and neck lesions in a cohort irradiated in childhood for tinea capitis treatment
  160. Thyroid hormone as a regulator of tumor induced angiogenesis
  161. Tumor-in-Tumor of the Thyroid With Basaloid Differentiation: A Lesion With a Solid Cell Nest Neoplastic Component?
  162. Small papillary thyroid cancers—is BRAF of prognostic value?
  163. EBV interferes with the sensitivity of Burkitt lymphoma Akata cells to etoposide
  164. How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer
  165. mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics
  166. Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells
  167. Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas
  168. Multicentre validation study of nucleic acids extraction from FFPE tissues
  169. Alopecia in women submitted to childhood X-ray epilation for tinea capitis treatment
  170. Review Article: The Familial Counterparts of Follicular Cell—Derived Thyroid Tumors
  171. Identification of a paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPAR ) rearrangement mosaicism in a patient with an autonomous functioning follicular thyroid carcinoma bearing an activating mutation in the TSH receptor
  172. Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma
  173. An assessment of the clonality of the components of canine mixed mammary tumours by mitochondrial DNA analysis
  174. Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations
  175. A follicular variant of papillary thyroid carcinoma in struma ovarii. Case report with unique molecular alterations
  176. IsBRAFmutation screening useful for preoperative risk stratification in papillary thyroid cancer?
  177. BRAFV600Emutation in papillary thyroid carcinoma: a potential target for therapy?
  178. Germline variation of the melanocortin-1 receptor does not explain shared risk for melanoma and thyroid cancer
  179. Mitochondria and cancer
  180. How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer
  181. Cribriform-Morular Variant of Papillary Thyroid Carcinoma
  182. Mitochondria and Oncocytomas
  183. Cyclic AMP Inhibits the Proliferation of Thyroid Carcinoma Cell Lines through Regulation of CDK4 Phosphorylation
  184. Acquisition ofBRAFgene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma
  185. Follicular thyroid carcinoma with an unusual glomeruloid pattern of growth
  186. Optimization of methods to assess mitochondrial DNA in archival paraffin-embedded tissues from mammary canine tumors
  187. Intragenic Mutations in Thyroid Cancer
  188. GRIM-19 in Health and Disease
  189. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAFV600E but not KRAS mutations
  190. Loss of heterozygosity at 19p13.2 and 2q21 in tumours from familial clusters of non-medullary thyroid carcinoma
  191. Molecular and Genotypic Characterization of Human Thyroid Follicular Cell Carcinoma–Derived Cell Lines
  192. A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation
  193. Thyroid hormone receptor   mutations in the 'hot-spot region' are rare events in thyroid carcinomas
  194. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas
  195. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal
  196. The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma
  197. H-RAS 81 polymorphism is significantly associated with aneuploidy in follicular tumors of the thyroid
  198. PAX8-PPARγ Rearrangement Is Frequently Detected in the Follicular Variant of Papillary Thyroid Carcinoma
  199. Diagnostic Criteria in Well-Differentiated Thyroid Carcinomas
  200. Reply to: Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas
  201. Mitochondrial D-Loop instability in thyroid tumours is not a marker of malignancy
  202. Molecular pathology of well-differentiated thyroid carcinomas
  203. A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma
  204. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness
  205. A stem cell role for thyroid solid cell nests
  206. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hürthle cell) tumours of the thyroid
  207. Cystic Tumor of the Atrioventricular Node of the Heart Appears to Be the Heart Equivalent of the Solid Cell Nests (Ultimobranchial Rests) of the Thyroid
  208. Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes
  209. Mutation analysis of B-RAF gene in human gliomas
  210. BRAFMutations Are Not a Major Event in Post-Chernobyl Childhood Thyroid Carcinomas
  211. Telomerase expression and proliferative activity suggest a stem cell role for thyroid solid cell nests
  212. Core I gene is overexpressed in Hürthle and non-Hürthle cell microfollicular adenomas and follicular carcinomas of the thyroid
  213. BRAF mutations are associated with some histological types of papillary thyroid carcinoma
  214. Germline Succinate Dehydrogenase Subunit D Mutation Segregating with Familial Non-RET C Cell Hyperplasia
  215. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC
  216. E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas
  217. Immunohistochemical study of heat shock proteins 27, 60 and 70 in the normal human adrenal and in adrenal tumors with suppressed ACTH production
  218. Vascular Invasion in Thyroid and Gastric Carcinomas
  219. p63 Expression in Solid Cell Nests of the Thyroid: Further Evidence for a Stem Cell Origin
  220. Mucoepidermoid carcinoma of the thyroid: a tumour histotype characterised by P-cadherin neoexpression and marked abnormalities of E-cadherin/catenins complex
  221. Diffuse (or multinodular) follicular variant of papillary thyroid carcinoma: a clinicopathologic and immunohistochemical analysis of ten cases of an aggressive form of differentiated thyroid carcinoma
  222. Microsatellite instability, mitochondrial DNA large deletions, and mitochondrial DNA mutations in gastric carcinoma
  223. Abnormalities of the E-cadherin/catenin adhesion complex in classical papillary thyroid carcinoma and in its diffuse sclerosing variant
  224. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma
  225. Fetal adenomas and minimally invasive follicular carcinomas of the thyroid frequently display a triploid or near triploid DNA pattern
  226. Extended structural variation of a pentanucleotide repeat in the GSTP1 gene: characterisation in a normal population and in thyroid and gastric tumours
  227. Comments on: Mutations in Mitochondrial Control Region DNA in Gastric Tumours of Japanese Patients, Tamura, et al. Eur J Cancer 1999, 35, 316–319
  228. Sporadicret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms?
  229. Benign and malignant thyroid lesions show instability at microsatellite loci
  230. E-cadherin gene alterations are rare events in thyroid tumors
  231. Chromosome analysis of 73 thyroid neoplasms
  232. Correspondence
  233. Thyroid nodular hyperplasia
  234. Cytogenetic findings in eleven gastric carcinomas
  235. Cytogenetic findings in 18 follicular thyroid adenomas
  236. Clonal cytogenetic abnormalities and telomeric associations in a fibroxanthoma of the stomach
  237. Loss of Y chromosome in gastric carcinoma
  238. Signet Ring Cell Carcinoma of the Stomach: A Morphometric, Ultrastructural, and DNA Cytometric Study